Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver findings in newly diagnosed, treatment-naive patients with Crohn's disease: a preliminary study of MRI proton density fat fraction and extracellular volume fraction.

BMC medical imaging·2026
Same author

A novel monocyte-based biomarker of cardiovascular risk: comparison with traditional cardiovascular risk calculators.

American journal of preventive cardiology·2026
Same author

Neuroprotective role of Faecalibacterium prausnitzii-derived butyrate in diabetic gastrointestinal autonomic neuropathy.

Journal of genetics and genomics = Yi chuan xue bao·2026
Same author

Metagenomic sequencing reveals high reproducibility of human donor microbiota transplanted into germ-free mice via lower gut route.

Journal of Zhejiang University. Science. B·2026
Same author

Pitfalls in the pharmacotherapy of hypertension.

Clinical medicine (London, England)·2026
Same author

Relationship Between Gut Microbiota and Cancer Neuro-Immunity.

Microbial biotechnology·2026

Related Experiment Video

Updated: Jun 16, 2026

Platelet-based Detection of Nitric Oxide in Blood by Measuring VASP Phosphorylation
07:13

Platelet-based Detection of Nitric Oxide in Blood by Measuring VASP Phosphorylation

Published on: January 7, 2019

Pyridoxine increases nitric oxide biosynthesis in human platelets.

Yong Wu1, Yuan Liu, Yi Han

  • 1Atherosclerosis Research Centre, Key Laboratory of Human Functional Genomics, and the Affiliated Ophthalmic Hospital of Nanjing Medical University, Nanjing 210029, China.

International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift Fur Vitamin- Und Ernahrungsforschung. Journal International De Vitaminologie Et De Nutrition
|January 29, 2010
PubMed
Summary

Pyridoxine, a vitamin B6 derivative, inhibits platelet aggregation and boosts nitric oxide (NO) production in platelets. This effect is mediated by enhancing phosphatidylinositol 3-kinase (PI3K) and Akt signaling pathways, leading to increased NO synthase activity.

More Related Videos

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
08:32

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells

Published on: March 16, 2017

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements
07:19

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Published on: July 29, 2021

Related Experiment Videos

Last Updated: Jun 16, 2026

Platelet-based Detection of Nitric Oxide in Blood by Measuring VASP Phosphorylation
07:13

Platelet-based Detection of Nitric Oxide in Blood by Measuring VASP Phosphorylation

Published on: January 7, 2019

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
08:32

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells

Published on: March 16, 2017

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements
07:19

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Published on: July 29, 2021

Area of Science:

  • Biochemistry
  • Cardiovascular Research
  • Pharmacology

Background:

  • Platelet activation and aggregation are central to thrombotic diseases.
  • Platelet-derived nitric oxide (NO) plays a crucial role in inhibiting platelet activity.
  • Pyridoxine (Vitamin B6) may offer cardiovascular benefits by influencing NO biosynthesis.

Purpose of the Study:

  • To investigate whether pyridoxine enhances nitric oxide (NO) synthesis within platelets.
  • To elucidate the underlying molecular mechanisms by which pyridoxine affects platelet NO production.

Main Methods:

  • Platelets from healthy subjects were treated with pyridoxine in vitro.
  • Platelet aggregation was assessed using Born aggregometry.
  • Intraplatelet cyclic guanosine-3',5'-monophosphate (cGMP), NO synthase type 3 (NOS-3) phosphorylation, Akt phosphorylation, and phosphatidylinositol 3-kinase (PI3K) activity were measured.

Main Results:

  • Pyridoxine significantly inhibited platelet aggregation induced by ADP or thrombin.
  • Pyridoxine increased platelet NO production and intraplatelet cGMP levels.
  • Pyridoxine enhanced PI3K activity, leading to increased Akt and NOS-3 phosphorylation at serine-1177.

Conclusions:

  • Pyridoxine effectively elevates platelet NO biosynthesis, thereby exerting anti-platelet effects.
  • The mechanism involves the pyridoxine-induced improvement of PI3K activity and subsequent activation of the Akt/NOS-3 pathway.
  • This study reveals a novel regulatory pathway for NOS-3 activity in platelets.